18 Januar 2023 07:27 PM Eastern Daylight Time

BUSINESS WIRE

RevBio erhält Genehmigung für klinische Studie in Italien für sein regeneratives Biomaterial

In voller Größe anschauen

Opens in new window

Download-Formate

Volle Größe JPEG, 8192x2125, 3.6 MB
Klein JPEG, 480x125, 37.9 KB
Vorschau im JPEG-Format JPEG, 144x37, 9.7 KB
Kleinbild im JPEG-Format JPEG, 120x31, 7.1 KB

Smart Multimedia-Galerie

Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire)

Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire)

View and Share Foto

http://www.businesswire.de/multimedia/de/20230117006137/de/5373746/

Share

E-Mail

Alle Nachrichten | Nachrichten mit Fotos & Multimedia > Pressemitteilung: RevBio erhält Genehmigung für klinische Studie ...

Weitere Business Wire-Websites